Enzo Biochem (NYSE:ENZ – Get Free Report) issued its quarterly earnings results on Monday. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.
Enzo Biochem Trading Down 4.7 %
Shares of Enzo Biochem stock traded down $0.02 on Monday, reaching $0.47. 14,647 shares of the stock were exchanged, compared to its average volume of 118,050. Enzo Biochem has a twelve month low of $0.41 and a twelve month high of $1.30. The business has a 50 day moving average price of $0.57 and a two-hundred day moving average price of $0.88.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Enzo Biochem in a research note on Saturday. They set a “hold” rating on the stock.
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Stories
- Five stocks we like better than Enzo Biochem
- Differences Between Momentum Investing and Long Term Investing
- Can TikTok Stock Picks Really Make You Rich?
- Investing In Automotive Stocks
- The “Quality” Rotation: Back to Basics Investing
- What is a Low P/E Ratio and What Does it Tell Investors?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
